These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 8643695)
21. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis. Mitosek-Szewczyk K; Tabarkiewicz J; Wilczynska B; Lobejko K; Berbecki J; Nastaj M; Dworzanska E; Kolodziejczyk B; Stelmasiak Z; Rolinski J J Neurol Sci; 2013 Sep; 332(1-2):35-40. PubMed ID: 23835090 [TBL] [Abstract][Full Text] [Related]
22. Development of oral cladribine for the treatment of multiple sclerosis. Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304 [TBL] [Abstract][Full Text] [Related]
23. [Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results]. Grieb P; Stelmasiak Z Neurol Neurochir Pol; 1995; 29(1):69-76. PubMed ID: 7596480 [TBL] [Abstract][Full Text] [Related]
24. [A plan for risk management in the treatment of multiple sclerosis with movectro (cladribine tablets)]. Khachanova NV Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):99-104. PubMed ID: 21916164 [No Abstract] [Full Text] [Related]
27. Whole brain volume changes in patients with progressive MS treated with cladribine. Filippi M; Rovaris M; Iannucci G; Mennea S; Sormani MP; Comi G Neurology; 2000 Dec; 55(11):1714-8. PubMed ID: 11113227 [TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ; Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029 [TBL] [Abstract][Full Text] [Related]
29. Cladribine. Ortho Biotech Inc. Tortorella C; Rovaris M; Filippi M Curr Opin Investig Drugs; 2001 Dec; 2(12):1751-6. PubMed ID: 11892941 [TBL] [Abstract][Full Text] [Related]
30. [Experience in the use of cladribine for the treatment of patients with highly active forms of multiple sclerosis in the Moscow region]. Yakushina TI; Yakushin DM; Lizhdvoy VY; Belova YA Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(6):74-79. PubMed ID: 39072570 [TBL] [Abstract][Full Text] [Related]
31. A comparison of two neurologic scoring instruments for multiple sclerosis. Koziol JA; Frutos A; Sipe JC; Romine JS; Beutler E J Neurol; 1996 Mar; 243(3):209-13. PubMed ID: 8936349 [TBL] [Abstract][Full Text] [Related]
32. The effect of cladribine on T(1) 'black hole' changes in progressive MS. Filippi M; Rovaris M; Rice GP; Sormani MP; Iannucci G; Giacomotti L; Comi G J Neurol Sci; 2000 May; 176(1):42-4. PubMed ID: 10865091 [TBL] [Abstract][Full Text] [Related]
34. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510 [TBL] [Abstract][Full Text] [Related]
35. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375 [TBL] [Abstract][Full Text] [Related]
36. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S; Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565 [TBL] [Abstract][Full Text] [Related]
37. [Cladribin. Development of an oral formulation for the treatment of multiple sclerosis]. Hartung HP; Kieseier BC; Aktas O Nervenarzt; 2010 Feb; 81(2):194-202. PubMed ID: 20127230 [TBL] [Abstract][Full Text] [Related]
38. Cladribine for multiple sclerosis: review and current status. Sipe JC Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330 [TBL] [Abstract][Full Text] [Related]
39. New drugs may improve, complicate treatment for multiple sclerosis. Link H; Martin R Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513 [No Abstract] [Full Text] [Related]
40. Histological examination of the retinal ganglion layer in rabbits after experimental administration of the new immunosuppressive medicine--Cladribine. Kwietniewska M; Cybulska R; Kwietniewski P; Sekita-Krzak J; Czerny K Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):376-80. PubMed ID: 12898865 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]